C-erbB-4 Protein Expression in Human Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2000 Mar 29

PMID 10735500

Citations 33

Authors

T Y Kew

J A Bell

S E Pinder

H Denley

R Srinivasan

W J Gullick

R I Nicholson

R W Blamey

I O Ellis

Affiliations

Soon will be listed here.

Abstract

The Type 1 family of growth factor receptors includes epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3 and c-erbB-4. Overexpression of the first two members is associated with poorer prognosis in patients with breast carcinoma. In this study we examined the expression of c-erbB-4 protein using the monoclonal antibody HFR-1. A total of 127 consecutive cases of primary operable invasive breast carcinoma presenting between 1975 and 1977 were studied. All patients were managed by simple mastectomy or conservation surgery with radiotherapy and no adjuvant therapy given. Long-term follow-up was maintained. Routine, formalin-fixed, paraffin-embedded tumour samples were used and sections were stained immunohistochemically using the Duet StreptABC method. Immunoreactivity was classified using a simple semi-quantitative scoring method. Protein expression was generally low but definite positive cytoplasmic, membranous and nuclear reactivity was identified in 58%, 41% and 25% of cases respectively. Expression at all three sites demonstrated significant inverse associations were histological grade. In addition, membrane accentuation correlated inversely with the Nottingham Prognostic Index (NPI), while cytoplasmic reactivity showed a positive association with c-erbB-3 expression. No significant associations were found with disease-free interval or survival. The results of this study demonstrate that higher levels of c-erbB-4 protein expression are associated with a more differentiated histological phenotype in contrast to the other members of the Type 1 family. Larger series with extended follow-up will be required to ascertain definitively the prognostic value of c-erbB-4 expression in breast carcinoma.

Citing Articles

Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies.

Miano C, Romaniello D, Mazzeschi M, Morselli A, Da Pra S, Sacchi F Front Oncol. 2022; 12:831105.

PMID: 35664762 PMC: 9157648. DOI: 10.3389/fonc.2022.831105.

A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.

El-Gamal M, Mewafi N, Abdelmotteleb N, Emara M, Tarazi H, Sbenati R Molecules. 2021; 26(23).

PMID: 34885957 PMC: 8659013. DOI: 10.3390/molecules26237376.

ErbB4 3'-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer.

Tabatabian M, Mesrian Tanha H, Tabatabaeian H, Sadeghi S, Ghaedi K, Mohamadynejad P Indian J Clin Biochem. 2020; 35(1):115-120.

PMID: 32071504 PMC: 6995472. DOI: 10.1007/s12291-018-0793-3.

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2 Breast Cancer.

Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W Mol Ther Nucleic Acids. 2018; 10:317-330.

PMID: 29499944 PMC: 5862534. DOI: 10.1016/j.omtn.2017.12.015.

Breast cancers with and co-amplification favor distant metastasis and poor clinical outcome.

Guo P, Pu T, Chen S, Qiu Y, Zhong X, Zheng H Oncol Lett. 2017; 14(6):6562-6570.

PMID: 29181099 PMC: 5696709. DOI: 10.3892/ol.2017.7051.

References

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Haybittle J, Blamey R, Elston C, Johnson J, DOYLE P, Campbell F . A prognostic index in primary breast cancer. Br J Cancer. 1982; 45(3):361-6. PMC: 2010939. DOI: 10.1038/bjc.1982.62. View

Todd J, Dowle C, Williams M, Elston C, Ellis I, Hinton C . Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987; 56(4):489-92. PMC: 2001834. DOI: 10.1038/bjc.1987.230. View

Kageyama R, Merlino G, Pastan I . Epidermal growth factor (EGF) receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific factor. J Biol Chem. 1988; 263(13):6329-36. View

Lewis S, Locker A, Todd J, Bell J, Nicholson R, Elston C . Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol. 1990; 43(5):385-9. PMC: 502437. DOI: 10.1136/jcp.43.5.385. View

Lovekin C, Ellis I, Locker A, Robertson J, Bell J, Nicholson R . c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991; 63(3):439-43. PMC: 1971868. DOI: 10.1038/bjc.1991.101. View

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

Klijn J, Berns P, Schmitz P, Foekens J . The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992; 13(1):3-17. DOI: 10.1210/edrv-13-1-3. View

Holmes W, Sliwkowski M, Akita R, Henzel W, Lee J, Park J . Identification of heregulin, a specific activator of p185erbB2. Science. 1992; 256(5060):1205-10. DOI: 10.1126/science.256.5060.1205. View

10.

Ellis I, Galea M, Broughton N, Locker A, Blamey R, Elston C . Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992; 20(6):479-89. DOI: 10.1111/j.1365-2559.1992.tb01032.x. View

11.

Lemoine N, Barnes D, Hollywood D, Hughes C, Smith P, Dublin E . Expression of the ERBB3 gene product in breast cancer. Br J Cancer. 1992; 66(6):1116-21. PMC: 1978009. DOI: 10.1038/bjc.1992.420. View

12.

Plowman G, Culouscou J, Whitney G, Green J, Carlton G, Foy L . Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A. 1993; 90(5):1746-50. PMC: 45956. DOI: 10.1073/pnas.90.5.1746. View

13.

Hollywood D, Hurst H . A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J. 1993; 12(6):2369-75. PMC: 413467. DOI: 10.1002/j.1460-2075.1993.tb05891.x. View

14.

Chang C, LAZAR C, Walsh B, Komuro M, Collawn J, Kuhn L . Ligand-induced internalization of the epidermal growth factor receptor is mediated by multiple endocytic codes analogous to the tyrosine motif found in constitutively internalized receptors. J Biol Chem. 1993; 268(26):19312-20. View

15.

Plowman G, Green J, Culouscou J, Carlton G, Rothwell V, Buckley S . Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature. 1993; 366(6454):473-5. DOI: 10.1038/366473a0. View

16.

Wen D, Suggs S, Karunagaran D, Liu N, Cupples R, Luo Y . Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol. 1994; 14(3):1909-19. PMC: 358549. DOI: 10.1128/mcb.14.3.1909-1919.1994. View

17.

Pinder S, Ellis I, Galea M, ORouke S, Blamey R, Elston C . Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994; 24(1):41-7. DOI: 10.1111/j.1365-2559.1994.tb01269.x. View

18.

Zimonjic D, Alimandi M, Miki T, Popescu N, Kraus M . Localization of the human HER4/erbB-4 gene to chromosome 2. Oncogene. 1995; 10(6):1235-7. View

19.

Earp H, Dawson T, Li X, Yu H . Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995; 35(1):115-32. DOI: 10.1007/BF00694752. View

20.

Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R . Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995; 378(6555):390-4. DOI: 10.1038/378390a0. View